Neuroblastoma
📧 Sign up to get email alerts when something new happens for Neuroblastoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers [Phase 2, Phase 3]
The DETERMINE trial treatment arm 01 is evaluating Alectinib in adult, paediatric and teenage/young adult patients with ALK-positive cancers…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations [Phase 2, Phase 3]
An ongoing DETERMINE trial (arm 06) investigates capmatinib for MET-dysregulated cancers, with Phase 2/3 testing and current recruitment.
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults [Phase 1]
Phase 1 clinical trial update describing B7H3-targeted CAR T-cell therapy for recurrent/refractory pediatric solid tumors, including several…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults [Phase 1]
A Phase 1 trial update for EGFR806 CAR T cell immunotherapy in pediatric and young adult patients with recurrent/refractory solid tumors; th…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors [Phase 1]
GAIA-102 is being evaluated in a Phase 1 trial for refractory/relapsed neuroblastoma and other pediatric solid tumors, and the study is curr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. [Phase 1]
Phase 1 clinical study evaluating the safety of Lutetium-177 DOTATATE peptide receptor radionuclide therapy in children with neuroblastoma e…
-
EMA withdrawal · 2025-11-14EMA Refused: Kizfizo (temozolomide) — ORPHELIA Pharma
The EMA refused marketing authorization for Kizfizo (temozolomide) for neuroblastoma, in an application from ORPHELIA Pharma.
-
CLINICAL_TRIALS research · 2025-11-13Clinical Trial Update: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
This clinical trial update describes biomarker analysis in tumor tissue from patients with newly diagnosed neuroblastoma or ganglioneuroblas…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial [Phase 2]
This update reports on a Phase 2 pediatric MATCH trial evaluating selpercatinib for patients with activating RET gene alterations across adv…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Genomic Structural Variation in Cancer Susceptibility
This clinical trial update discusses ongoing research on genomic structural variation in cancer susceptibility and lists several cancer cond…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
A clinical trial update reports fecal microbiota transplant for neuroblastoma in a single patient, and the study is no longer available.
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial [Phase 1]
Phase 1 GD2-targeted CAR-T cell therapy (GD2CART) for recurrent/refractory neuroblastoma and osteosarcoma has a suspended status as of the u…
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma [Phase 1]
Phase I study of 131-I mIBG followed by nivolumab and dinutuximab beta for children with relapsed/refractory neuroblastoma is listed as acti…
-
CLINICAL_TRIALS research · 2025-10-21Clinical Trial Update: Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma [Phase 2]
This clinical trial update describes a Phase 2 study evaluating myeloablative consolidation therapy with tandem autologous stem cell rescue …
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 pediatric MATCH trial evaluating larotrectinib in patients with NTRK gene fusions has posted results; the study remains active but n…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors [Phase 1]
Phase 1 pediatric trial evaluating alpha/beta CD19+ depleted haploidentical transplantation in combination with Zoledronic acid (Zometa) for…
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Clinical trial evaluating molecular characteristics of neuroblastic tumors and how these features correlate with clinical outcomes in neurob…
-
FDA approval · 2025-10-10FDA Approved: UNITUXIN — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for UNITUXIN (dinutuximab) from United Therapeutics Corporation.
-
CLINICAL_TRIALS trial_result · 2025-10-10Clinical Trial Update: Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors [Phase 1]
A Phase 1 trial evaluating ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refracto…
-
CLINICAL_TRIALS trial_result · 2025-10-07Clinical Trial Update: A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma [Phase 2]
Phase 2 trial evaluating Hu3F8/GM-CSF immunotherapy plus isotretinoin in patients in first remission of high-risk neuroblastoma has complete…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is evaluating infusion of NY-ESO-1–specific TCR-engineered lymphocytes in patients with NY-ESO-1-expressing…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma [EARLY_Phase 1]
This EARLY Phase 1 trial evaluated reduced-dose radiotherapy for high-risk neuroblastoma and has completed.
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
A clinical trial evaluating imaging agents targeting somatostatin receptors and norepinephrine transporters for diagnosis and staging of neu…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors [Phase 1]
Phase 1 study evaluating flavored oral irinotecan VAL-413 (Orotecan) with temozolomide for recurrent pediatric solid tumors is currently rec…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma [Phase 1]
Phase 1 clinical trial evaluating autologous NKT cells engineered with a GD2-targeted CAR and interleukin-15 for neuroblastoma in children; …